FDA approves single tablet regimen

Organisation: Position: Deadline Date: Location:

The US Food and Drug Administration (FDA) has approved Triumeq, ViiV Healthcare’s single-tablet, triple-combination antiretroviral (ARV) regimen, as a first-line therapy to treat HIV. The tablet is comprised of the integrase inhibitor Tivicay (dolutegravir) plus Epzicom (abacavir and lamivudine) and is the first single-tablet regimen to receive approval that does not contain Truvada (tenofovir/emtricitabine). Consequently, Triumeq is an option for those who have impaired kidney function.

Before starting on the drug, people with HIV should receive the HLA-B*5701 genetic screen, otherwise known as the abacavir hypersensitivity reaction test, which determines if someone is likely to develop a kind of allergic reaction to the abacavir component.

The FDA approved Triumeq based on the results from various randomized controlled trials in treatment-native people with HIV, including: SINGLE, which tested the drug against Atripla (efavirenz/tenofovir/emtricitabine); SPRING-2, which put Tivicay up against Isentress (raltegravir); and FLAMINGO, in which dolutegravir bested Prezista (ritonavir-boosted darunavir).

Triumeq alone is not recommended for people with known HIV resistance to abacavir, lamivudine or any of the approved integrase inhibitors.

Full Aidsmeds report

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.